Naples Laser & Skin

Molecular Profile

Minoxidil
Loniten — Oral vasodilator / hair loss agent

Chemical formula	`C₉H₁₅N₅O`
Class	Small-molecule prodrug; activated by hepatic / follicular sulfotransferase SULT1A1 to minoxidil sulfate
Molecular weight	≈ 209.25 g/mol
Form	Oral capsule / tablet Typically compounded at 0.5–5 mg for hair loss vs. the original 2.5–10 mg antihypertensive tablet
Half-life	≈ 4 hours
Origin	FDA-approved in 1979 as Loniten for severe, refractory hypertension; its hair-growth side effect was noted almost immediately and led to the later development of topical minoxidil

HOW IT WORKS

Minoxidil opens ATP-sensitive potassium channels in vascular smooth muscle, relaxing blood vessels and lowering blood pressure — its original, still-approved mechanism. In hair follicles, the same vasodilating and potassium-channel activity is believed to prolong the growth (anagen) phase and increase blood flow to the follicle, though the precise hair-growth mechanism remains incompletely understood.

‍

WHAT TO EXPECT

Severe refractory hypertension (FDA-approved indication, brand Loniten)
Low-dose oral minoxidil (LDOM) for androgenetic and other hair loss — off-label, compounded
Frequently paired with finasteride or spironolactone in dermatology protocols

BEFORE YOU START

Carries an FDA black-box warning for pericardial effusion, cardiac tamponade, and angina exacerbation at antihypertensive doses
Hair-growth doses are a fraction of the blood-pressure dose, but hypertrichosis (unwanted body/facial hair growth) remains a common side effect, more so in women
A dermatology-specific extended-release oral formulation (VDPHL01) is in Phase 3 trials, aiming to be the first minoxidil product ever FDA-approved specifically for hair loss